HOME >> MEDICINE >> NEWS
OHSU Scientists Begin Human Trials Of A Drug Aimed At The Underlying Cause Of Chronic Myelogenous Leukemia

For the first time, patients with a specific form of leukemia will receive an investigational drug therapy aimed precisely at the molecules causing their cancer. The first patient, 68-year-old Bud Romine from Tillamook, Ore., will take his first dose of the experimental drug on Thursday, June 25, 1998, at Oregon Health Sciences University.

The often fatal blood disease is called chronic myelogenous leukemia and strikes about 6,000 Americans annually. "The highly targeted drug eliminates leukemia cells in mice, and will be used for the first time in humans this summer," explained Brian Druker, M.D., principal investigator of the trial and associate professor of hematology and medical oncology at Oregon Health Sciences University.

Until now, patients with chronic myelogenous leukemia have been treated with chemotherapy aimed at killing rapidly dividing cells or they have undergone bone marrow transplantation aimed at replacing their diseased marrow.

"This experimental therapy is different than chemotherapy because it targets leukemia cells and leaves normal cells alone," explained Druker.

"When I was diagnosed with leukemia four years ago I began chemotherapy," said Romine. "But I never went into remission. Then I read about Brian Druker's work in The Oregonian and I wrote him a letter."

Romine will be the first of about 50 patients to enter the clinical trial. Within a year, physicians expect to determine the success of the therapy. All patients in the trial will receive the drug, and dosages will be escalated until either significant benefits or side effects appear.

The multicenter trial was designed by the Oregon Cancer Center based at OHSU and will also be conducted at UCLA and M.D. Anderson Medical Center in Texas.

"The commitment of the Oregon Cancer Center to controlling cancer and leukemia is based upon two fundamental premises. First, you can't prevent or cure cance
'"/>

Contact: Henry Sessions
sessionh@ohsu.edu
503-494-8231
Oregon Health & Science University
25-Jun-1998


Page: 1 2 3 4

Related medicine news :

1. Scientists replicate hepatitis C virus in laboratory
2. Scientists identify brain regions that decide where we look
3. Scientists uncover new mechanism for the amygdala in fear recognition
4. Scientists identify protein critical to melanoma growth
5. Scientists discover recipe for life: eating the Polymeal cuts heart disease by 76%
6. Scientists study fish oil diet in bid to cut heart attack risks
7. Scientists discover enzyme crucial to the transportation of proteins within cells
8. Scientists turn on the gender lens on cardiovascular disease research
9. Scientists stalk PPAR-gamma, find novel cancer connection
10. Scientists align billion-year-old protein with embryonic heart defects
11. Scientists pinpoint flaw, offer new promise for stroke treatment

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/10/2019)... Calif. (PRWEB) , ... October 10, 2019 , ... Caring.com, ... Living Report on the Best and Worst Places for Seniors to Live. All 50 ... community engagement, transportation, quality of life and workforce development. , According to the ...
(Date:10/8/2019)... , ... October 08, 2019 , ... SoCal Adolescent Wellness ... happy to announce the expansion of our services to better serve the families in ... over this last year to see the extraordinary impact this pre-intervention program has on ...
(Date:10/8/2019)... ... October 08, 2019 , ... ... CT, help patients with missing teeth restore their smiles with long-lasting dental ... surgeons relies on advanced i-CAT® 3D Cone Beam CT imaging, X-Guideā„¢ software and ...
(Date:10/8/2019)... ... October 08, 2019 , ... At the 13th ... President Gregg Church will inform conference attendees how the 4medica Perfect ... starting with the right, clean patient data. The single platform interfaces to core ...
(Date:10/8/2019)... (PRWEB) , ... October 08, 2019 , ... ... MCN Healthcare to seamlessly integrate skills and procedures content from Dynamic ... to help nurses and allied health professionals master critical skills. MCN provides custom ...
Breaking Medicine News(10 mins):
(Date:10/17/2019)... HILLS, Calif. (PRWEB) , ... October 17, 2019 , ... ... Allergan of its Biocell brand of textured implants is the subject of a September ... F.I.C.S., F.A.C.S., aka Dr. J says that the Allergan recall has revived a number ...
(Date:10/15/2019)... , ... October 14, 2019 ... ... LP2 linearity and calibration verification kit, for Roche cobas® analyzers, Order No. ... Apolipoprotein B (Apo-B). Each VALIDATE® LP2 kit, liquid, ready-to-use, and prepared ...
(Date:10/15/2019)... ... October 14, 2019 , ... An October 4 article on ... correlation between tooth loss and heart disease. The researchers found that individuals between 40 ... of also having heart-related problems, compared to just seven percent for those who never ...
Breaking Medicine Technology:
Cached News: